Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Cardiovascular (CV) disease is the leading cause of death globally, exacerbated by an aging population.
• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Statin therapy is the first-line treatment for LDL-C reduction, but many patients experience recurrent events despite maximal statin use.

Purpose of the Study:

• To review current clinical guidelines and evidence for lipid-lowering therapies in ASCVD.
• To focus on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and their role in CV risk reduction.
• To explore strategies for secondary prevention in high-risk patients with persistent hypercholesterolemia.

Main Methods:

• Literature search of PubMed for English articles on lipid-lowering therapies and CV risk reduction.
• Inclusion of emerging therapies and CV outcomes trials, with a specific focus on PCSK9 inhibitors.
• Analysis of recent clinical trial data for cholesterol-lowering efficacy and CV outcomes.

Main Results:

• Patients with ASCVD may have recurrent ischemic events despite maximally tolerated statin therapy.
• High-risk subgroups, including those with familial hypercholesterolemia, diabetes, or statin intolerance, require aggressive lipid lowering.
• PCSK9 inhibitors show promise in reducing CV risk in specific patient populations.

Conclusions:

• Optimal therapeutic strategies must address unmet needs in patients with persistent CV risk despite statin therapy.
• Aggressive lipid lowering is crucial for very high-risk populations with multiple risk factors.
• PCSK9 inhibitors represent a significant advancement in managing hypercholesterolemia and reducing CV risk for secondary prevention.